$355 Million is the total value of DAFNA Capital Management LLC's 79 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 34.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Sell | ASCENDIS PHARMA A/Ssponsored adr | $15,902,792 | +13.5% | 130,212 | -4.1% | 4.48% | +18.8% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $12,463,508 | -8.0% | 316,092 | -15.8% | 3.51% | -3.7% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $11,380,839 | +20.3% | 477,785 | -0.4% | 3.20% | +25.9% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $8,733,572 | +2.6% | 73,121 | -8.8% | 2.46% | +7.4% |
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $8,510,065 | +5.9% | 468,358 | -13.0% | 2.40% | +10.9% |
| DXCM | Sell | DEXCOM INC | $7,649,588 | +30.9% | 67,552 | -6.9% | 2.15% | +37.0% |
| EWTX | Sell | EDGEWISE THERAPEUTICS INC | $6,855,576 | -10.8% | 766,843 | -1.8% | 1.93% | -6.6% |
| ACET | Sell | ADICET BIO INC | $5,646,093 | -57.6% | 631,554 | -32.5% | 1.59% | -55.6% |
| VKTX | Sell | VIKING THERAPEUTICS INC | $4,902,598 | +226.2% | 521,553 | -5.6% | 1.38% | +241.8% |
| MRUS | Sell | MERUS N V | $4,175,245 | -24.7% | 269,893 | -2.5% | 1.18% | -21.2% |
| ETNB | Sell | 89BIO INC | $4,126,722 | +8.8% | 324,173 | -50.5% | 1.16% | +13.9% |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $2,941,048 | -37.1% | 142,217 | -20.4% | 0.83% | -34.1% |
| Sell | VIGIL NEUROSCIENCE INC | $2,110,575 | +7.2% | 168,846 | -22.0% | 0.59% | +12.1% | |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $1,954,052 | +6.2% | 473,136 | -17.7% | 0.55% | +11.1% |
| KURA | Sell | KURA ONCOLOGY INC | $1,796,769 | -36.2% | 144,784 | -29.8% | 0.51% | -33.2% |
| KROS | Sell | KEROS THERAPEUTICS INC | $1,584,660 | +8.0% | 33,000 | -15.4% | 0.45% | +12.9% |
| ORIC | Sell | ORIC PHARMACEUTICALS INC | $1,556,356 | +17.6% | 264,237 | -36.1% | 0.44% | +23.0% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $1,072,540 | -82.0% | 171,059 | -90.0% | 0.30% | -81.2% |
| SURF | Sell | SURFACE ONCOLOGY INC | $642,060 | -43.9% | 783,000 | -28.8% | 0.18% | -41.2% |
| KNTE | Sell | KINNATE BIOPHARMA INC | $433,149 | -53.6% | 71,008 | -9.1% | 0.12% | -51.4% |
| Sell | THESEUS PHARMACEUTICALS INC | $407,658 | -14.2% | 81,859 | -0.0% | 0.12% | -10.2% | |
| MGNX | Sell | MACROGENICS INC | $267,588 | -22.7% | 39,879 | -60.1% | 0.08% | -19.4% |
| SCYX | Sell | SCYNEXIS INC | $239,100 | -75.0% | 153,269 | -61.6% | 0.07% | -74.0% |
| BDTX | Sell | BLACK DIAMOND THERAPEUTICS I | $175,500 | -66.9% | 97,500 | -68.9% | 0.05% | -65.7% |
| Sell | REUNION NEUROSCIENCE INC | $42,911 | -68.9% | 47,679 | -50.6% | 0.01% | -67.6% | |
| VERO | Exit | VENUS CONCEPT INC | $0 | – | -968,187 | -100.0% | -0.12% | – |
| OTIC | Exit | OTONOMY INC | $0 | – | -1,470,199 | -100.0% | -0.12% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -81,200 | -100.0% | -0.12% | – |
| PRQR | Exit | PROQR THERAPEUTICS NV | $0 | – | -649,383 | -100.0% | -0.13% | – |
| CMPS | Exit | COMPASS PATHWAYS PLCsponsored ads | $0 | – | -47,390 | -100.0% | -0.14% | – |
| GHRS | Exit | GH RESEARCH PLCordinary shares | $0 | – | -52,631 | -100.0% | -0.16% | – |
| MEIP | Exit | MEI PHARMA INC | $0 | – | -1,767,146 | -100.0% | -0.18% | – |
| GMDA | Exit | GAMIDA CELL LTD | $0 | – | -614,896 | -100.0% | -0.26% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -74,953 | -100.0% | -0.26% | – |
| Exit | AERIE PHARMACEUTICALS INCnote 1.500%10/0 | $0 | – | -1,500,000 | -100.0% | -0.40% | – | |
| MDWD | Exit | MEDIWOUND LTD | $0 | – | -1,428,571 | -100.0% | -0.53% | – |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -307,232 | -100.0% | -1.25% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -110,100 | -100.0% | -4.48% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.